|
Market Closed -
NSE India S.E.
04:35:10 28/08/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 1,920.00 INR | +0.35% |
|
+0.93% | +11.65% |
| 05/08 | CRISIL Keeps AAA Rating on Sun Pharmaceutical's Bank Facilities | MT |
| 01/08 | Sun Pharmaceutical Industries Limited, Q1 2027 Earnings Call, Jul 31, 2026 |
| Market Cap | 4,60700Cr 4.82TCr 4.15TCr 3.89TCr 3.55TCr 6.7TCr 6.72TCr 46TCr 18TCr 2,32500Cr 18TCr 18TCr 7,71100Cr | P/E 2027 * |
35.4x | P/E 2028 * | 30x |
|---|---|---|---|---|---|
| Enterprise Value | 4,33600Cr 4.54TCr 3.91TCr 3.67TCr 3.35TCr 6.3TCr 6.32TCr 43TCr 17TCr 2,18900Cr 17TCr 17TCr 7,25800Cr | EV / Sales 2027 * |
6.66x | EV / Sales 2028 * | 5.85x |
| Free-Float |
44.39% | Yield 2027 * |
0.89% | Yield 2028 * | 1.03% |
Last Transcript : Sun Pharmaceutical Industries Ltd.
| 1 day | +0.35% | ||
| 1 week | +0.93% | ||
| Current month | -3.54% | ||
| 1 month | -3.51% | ||
| 3 months | +6.71% | ||
| 6 months | +10.54% | ||
| Current year | +11.65% |
| 1 week | 1,892.6 |  | 1,931 |
| 1 month | 1,868.3 | | 2,046.9 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.35% | +0.93% | +20.41% | +72.72% | 4.82TCr | |
| -0.08% | -0.21% | +56.71% | +119.95% | 4TCr | |
| +0.15% | +6.34% | +21.40% | +88.46% | 1.24TCr | |
| +0.25% | -0.61% | -10.44% | +15.76% | 1.2TCr | |
| +0.19% | 0.00% | +29.35% | +151.21% | 934.62Cr | |
| +0.07% | +3.80% | +30.19% | +45.41% | 775.13Cr | |
| +2.24% | +8.50% | +30.72% | +232.43% | 742.6Cr | |
| +0.04% | +0.37% | +48.28% | -11.16% | 721.72Cr | |
| -0.53% | -1.53% | -36.09% | +15.18% | 530.08Cr | |
| +0.38% | -2.27% | +43.57% | +106.24% | 464.98Cr | |
| Average | +0.31% | +1.86% | +23.41% | +83.62% | 1.54TCr | |
| Weighted average by Cap. | +0.24% | +1.31% | +29.08% | +87.96% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 65TCr 681.16Cr 586.96Cr 550.33Cr 502.37Cr 946.39Cr 949.4Cr 6.53TCr 2.55TCr 33TCr 2.56TCr 2.5TCr 1,09000Cr | 73TCr 762.78Cr 657.29Cr 616.27Cr 562.57Cr 1.06TCr 1.06TCr 7.31TCr 2.85TCr 37TCr 2.86TCr 2.8TCr 1,22000Cr |
| Net income | 13TCr 135.67Cr 116.91Cr 109.61Cr 100.06Cr 188.5Cr 189.1Cr 1.3TCr 507.39Cr 6.55TCr 509.37Cr 498.28Cr 22TCr | 15TCr 160.76Cr 138.53Cr 129.88Cr 118.56Cr 223.35Cr 224.07Cr 1.54TCr 601.22Cr 7.76TCr 603.57Cr 590.43Cr 26TCr |
| Net Debt | -27TCr -283.2Cr -244.03Cr -228.8Cr -208.86Cr -393.47Cr -394.72Cr -2.71TCr -1.06TCr -14TCr -1.06TCr -1.04TCr -45TCr | -34TCr -354.09Cr -305.12Cr -286.08Cr -261.15Cr -491.97Cr -493.53Cr -3.39TCr -1.32TCr -17TCr -1.33TCr -1.3TCr -57TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/26/28 | ₹1,920.00 | +0.35% | 11,40,742 |
| 27/26/27 | ₹1,913.30 | +0.73% | 11,07,552 |
| 26/26/26 | ₹1,899.50 | -1.17% | 6,48,845 |
| 25/26/25 | ₹1,922.00 | +0.63% | 12,21,044 |
| 24/26/24 | ₹1,910.00 | +0.40% | 23,17,987 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
